{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:12:08Z","timestamp":1788484328589,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2024ZD0533000"],"award-info":[{"award-number":["2024ZD0533000"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2024ZD0533004"],"award-info":[{"award-number":["2024ZD0533004"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jchromb.2026.125259","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:31:44Z","timestamp":1787095904000},"page":"125259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and validation of an HPLC-MS\/MS method for the quantification of Aficamten in human plasma and urine and application to a clinical pharmacokinetic study"],"prefix":"10.1016","volume":"1283","author":[{"given":"Xiaofei","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2026.125259_bb0005","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jchromb.2026.125259_bb0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","article-title":"Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.jchromb.2026.125259_bb0015","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jchromb.2026.125259_bb0020","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jchromb.2026.125259_bb0025","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jchromb.2026.125259_bb0030","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.jchromb.2026.125259_bb0035","first-page":"e533","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchromb.2026.125259_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.jchromb.2026.125259_bb0045","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jchromb.2026.125259_bb0050","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s44161-024-00505-0","article-title":"Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy","volume":"3","author":"Hartman","year":"2024","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.jchromb.2026.125259_bb0055","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/00498254.2024.2389407","article-title":"In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor","volume":"54","author":"Sukhun","year":"2024","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jchromb.2026.125259_bb0060","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jchromb.2026.125259_bb0065","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2026.125259_bb0070","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cardfail.2023.07.003","article-title":"Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving disopyramide: REDWOOD-HCM cohort 3","volume":"29","author":"Owens","year":"2023","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.jchromb.2026.125259_bb0075","article-title":"Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: an analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials","author":"Rowin","year":"2025","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.jchromb.2026.125259_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.03.040","article-title":"Aficamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: 48-week results from FOREST-HCM","volume":"13","author":"Saberi","year":"2025","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.jchromb.2026.125259_bb0085","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","author":"Garcia-Pavia","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2026.125259_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1227470","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jchromb.2026.125259_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70006","article-title":"Pharmacokinetics, disposition, and biotransformation of the cardiac myosin inhibitor aficamten in humans","volume":"12","author":"Xu","year":"2024","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.jchromb.2026.125259_bb0100","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/00498254.2024.2381111","article-title":"Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of [(14)C]aficamten following single oral dose administration to rats","volume":"54","author":"Grillo","year":"2024","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jchromb.2026.125259_bb0105","series-title":"Chinese Pharmacopoeia, 2015 ed.","author":"National Medical Products Administration","year":"2015"},{"key":"10.1016\/j.jchromb.2026.125259_bb0110","author":"European Medicines Agency"},{"key":"10.1016\/j.jchromb.2026.125259_bb0115","author":"US Food and Drug Administration"},{"key":"10.1016\/j.jchromb.2026.125259_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/ansa.70079","article-title":"A novel ultra-performance liquid chromatography-electrospray ionisation-tandem mass spectrometry method for quantification of Imeglimin in human plasma: application to a bioequivalence study","volume":"7","author":"Wadie","year":"2026","journal-title":"Anal. Sci. Adv."},{"key":"10.1016\/j.jchromb.2026.125259_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2025.124576","article-title":"A novel ultra-sensitive LC-MS\/MS method for determination of elobixibat in human plasma; application to a bioequivalence study on healthy volunteers","volume":"1257","author":"Rezk","year":"2025","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2026.125259_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2026.118795","article-title":"Breaking barriers in brexpiprazole bioequivalence: a first-in-human UPLC-MS\/MS approach to circumvent clinical sampling constraints","volume":"227","author":"Wadie","year":"2026","journal-title":"Microchem. J."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S157002322600348X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S157002322600348X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:15:59Z","timestamp":1788480959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S157002322600348X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":26,"alternative-id":["S157002322600348X"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125259","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an HPLC-MS\/MS method for the quantification of Aficamten in human plasma and urine and application to a clinical pharmacokinetic study","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125259","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125259"}}